25

Mar2022

Supreme Court Dismisses Attorney General’s Application for Leave to Appeal FCA decision in PMPRB Alexion Soliris Matter

On September 29, 2021, the Attorney General of Canada applied for leave to appeal to the Supreme Court of Canada concerning the Federal Court of Appeal’s (FCA) July 2021 decision in Alexion Pharmaceuticals Inc v Canada (Attorney General). On March 24, 2022, the Supreme Court of Canada ... Read More

23

Feb2022

New PDCI Market Access INSIGHTS (Volume 2, Issue 2)

PDCI releases new issue of PDCI Market Access INSIGHTS, featuring research and opinion on the evolving state of private health insurance in Canada. Volume 2, Issue 2 AnalyticsOur analytics article features ... Read More

22

Feb2022

Quebec Court Strikes 2 of 3 PMPRB Changes

On February 18, 2022, the Quebec Court of Appeal ruled that two of the three major proposed changes to the PMPRB price regulations are unconstitutional: As more information becomes available, PDCI will share further insights and implications for ... Read More

14

Feb2022

Reminder: Form 3 filing is due to the PMPRB On March 1, 2022

This is a reminder to patentees of their filing requirements respecting revenues and development expenditures. These filing requirements are contained in section 5 of the Patented Medicines Regulations. The Annual Form 3 filing to the PMPRB is due on March 1, 2022. As ... Read More

31

Jan2022

Updates to the Ontario Guidelines for Drug Submission and Evaluation

The Ontario Ministry of Health has recently updated the Ontario Guidelines for Drug Submission and Evaluation (Guidelines). In an effort to reduce complexity and simplify their policy document, specific guidelines aiming to address individual product types are now available on the Ontario Ministry of Health website.... Read More

14

Jan2022

REGISTER NOW for PDCI’s Webinar: Impact and Implications of the Delayed Regulations and PMPRB Guidelines

Join us on January 25, 2022 for insights and guidance on the potential impact of delayed PMPRB Pricing Regulations and Guidelines. Health Canada’s announcement on December 23, 2021 delayed the coming into force date for the Patented Medicines Regulations by a further ... Read More

31

Dec2021

PDCI Year in Review

As 2021 comes to an end, PDCI is reflecting on the year we've had in Canadian market access. PDCI's 2021 Year in Review highlights important milestones that occurred in 2021 and looks forward at Trends to Watch in 2022. Click here for the PDF version... Read More

28

Dec2021

Further Delay to the PMPRB Guidelines and amended Regulations

Health Canada announced on December 23, 2021 that the coming into force of the Patented Medicines Regulations has been delayed for another 6 months to July 1, 2022. As a result, implementation of the New PMPRB Guidelines (which in part rely on the amended Regulations) are also delayed until July ... Read More

17

Dec2021

PDCI’s 2021 Census of Insurers

PDCI is pleased to announce the release of the 2021 update to the Census of Insurers. The Census of Insurers is available exclusively through the PDCI Market Access Toolkit. PDCI’s Census of Insurers estimates the market share and private covered lives by insurer across Canada. Private payer and access managers ... Read More

17

Dec2021

New PDCI Market Access INSIGHTS Volume 2, Issue 1

PDCI releases new issue of PDCI Market Access INSIGHTS, featuring research and opinion on the evolving state of private health insurance in Canada. VOLUME 2, ISSUE 1... Read More